For its fourth fiscal quarter (ending December 31), Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) has reported a 5% increase in E.P.S. from $0.75 a year ago to $0.79 in the current quarter. E.P.S. were $3.29 for the latest four quarters through December 31 versus $2.85 for the same period a year ago — an increase of 15%.
Recent Price Action
On 2/27/25, Amphastar Pharmaceuticals Inc (NASDAQ: AMPH) stock rose modestly by 0.9%, closing at $31.49. This advance was accompanied by normal trading volume. The stock has been weak relative to the market over the last nine months but has risen 0.9% during the last week.
Current PriceTarget Research Rating
Amphastar Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Amphastar Pharmaceuticals has a good Appreciation Score of 80 but a very low Power Rating of 11, with the Low Neutral Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment